- POSITIVE
Quarterly Revenue Edwards Lifesciences Jun-2026 Quarterly Revenue is $1,741 Million which is growth of 13.6% YoY.
- NEGATIVE
Quarterly Net Profit Edwards Lifesciences Jun-2026 Quarterly Net Profit is $242 Million which is growth of -26.7% YoY.
85.78-0.70(-0.81%)
3.5M
XNYS Volume
XNYS 07 Oct, 2026 5:30 PM (EDT)
Edwards Lifesciences quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Forecaster Analyst Estimates for Edwards Lifesciences share price target, revenues, EPS, net income and more
Edwards Lifesciences quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | 1,741 | 1,648.6 | 1,569.6 | 1,553.1 | 1,532.2 | 1,412.7 | 1,385.8 | 1,354.4 | 1,385.9 | 1,598.2 | 1,534.1 | 1,480.9 | 1,530.2 | |
Cost Of Rev. | 392.4 | 362.6 | 343 | 345.2 | 344.4 | 301.6 | 292.2 | 262.9 | 285.3 | 385.6 | 356.9 | 350.4 | 343 | |
Gross Profit | 1,348.6 | 1,286 | 1,226.6 | 1,207.9 | 1,187.8 | 1,111.1 | 1,093.6 | 1,091.5 | 1,100.6 | 1,212.6 | 1,177.2 | 1,130.5 | 1,187.2 | |
| 829.1 | 771.3 | 856.3 | 782.8 | 756.9 | 701.2 | 740.3 | 697.2 | 723.4 | 774.9 | 750 | 709.9 | 739 | ||
Operating Profit | 519.5 | 514.7 | 370.3 | 425.1 | 430.9 | 409.9 | 353.3 | 394.3 | 377.2 | 437.7 | 427.2 | 420.6 | 448.2 | |
| 30 | 33.5 | 35.9 | 38.6 | 37.4 | 36.5 | 44.2 | 24.3 | 15.5 | 16.5 | 16.8 | 15.1 | 9.1 | ||
Profit Before Tax | 519.8 | 459 | 90.4 | 348.4 | 400.2 | 433.9 | 390.1 | 402.8 | 386.6 | 409.4 | 421.7 | 439.3 | 338.5 | |
Tax | 278.4 | 78.3 | 26.2 | 56.1 | 64.3 | 70.3 | 45.1 | 40.7 | 20.2 | 58.4 | 52 | 55.6 | 33 | |
| 241.9 | 380.7 | 91.2 | 291.1 | 329.8 | 358 | 385.6 | 3,070.8 | 366.3 | 351.9 | 369.9 | 384.9 | 307.1 | ||
Diluted NI Avail to Com Stockholders Ann. | 241.9 | 380.7 | 91.2 | 291.1 | 329.8 | 358 | 385.6 | 3,070.8 | 366.3 | 351.9 | 369.9 | 384.9 | 307.1 | |
Basic EPS | 0.4 | 0.7 | 0.2 | 0.5 | 0.6 | 0.6 | 0.7 | 5.1 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | |
Diluted EPS After ExtraOrdinary | 0.5 | 0.9 | 0.5 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | 0.6 | 0.6 | 0.7 | |
Number Of Shares End | 576.4 | 579.2 | 580.6 | 584.7 | 587 | 586.9 | 589.9 | 597.2 | 602.1 | 601.6 | 605.2 | 607 | 606.9 | |
Net Income Continuing Discontinued Operations | 241.9 | 380.7 | 91.2 | 291.1 | 329.8 | 358 | 385.6 | 3,070.8 | 366.3 | 351.9 | 369.9 | 384.9 | 307.1 | |
Normalized Income | 269.7 | 514 | 287.9 | 392.1 | 390.3 | 377.9 | 327.9 | 402.8 | 375.4 | 394.9 | 385.1 | 386.8 | 414.4 | |
Interest Income | 30 | - | 56.3 | 38.6 | 37.4 | - | 64 | 24.3 | 15.5 | - | - | - | - | |
Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Net Interest Income | 30 | 33.5 | 35.9 | 38.6 | 37.4 | 36.5 | 44.2 | 24.3 | 15.5 | 16.5 | 16.8 | 15.1 | 9.1 | |
EBIT | 519.5 | 514.7 | 27.4 | 425.1 | 430.9 | 409.9 | 441.1 | 394.3 | 377.2 | 437.7 | 314.3 | 420.6 | 448.2 | |
EBITDA | 562.2 | 555.6 | 70.1 | 464.3 | 469 | 446.5 | 483.7 | 428.8 | 416.8 | 476.2 | 351 | 457.5 | 484.3 | |
Reconciled Cost Of Rev. | 392.4 | 362.6 | 343 | 345.2 | 344.4 | 301.6 | 292.2 | 262.9 | 285.3 | 385.6 | 356.9 | 350.4 | 343 | |
Reconciled Depr. | 42.7 | 40.9 | 42.7 | 39.2 | 38.1 | 36.6 | 42.6 | 34.5 | 39.6 | 38.5 | 36.7 | 36.9 | 36.1 | |
Profit From Continuing Operations | 241.4 | 380.7 | 91.2 | 290.3 | 331.5 | 356.4 | 384.3 | 3,069.4 | 365 | 351 | 369.7 | 383.7 | 305.5 | |
Normalized EBITDA | 608.5 | 716.3 | 385.1 | 582.3 | 535.8 | 461.6 | 462.9 | 472.5 | 424.9 | 526.4 | 368.3 | 459.7 | 603.1 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Edwards Lifesciences competitor comparison and performance snapshot within industry
Edwards Lifesciences annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue Edwards Lifesciences Dec-2025 Annual Revenue is $6,068 Million which is growth of 11.5% YoY.
- NEGATIVE
Annual Net Profit Edwards Lifesciences Dec-2025 Annual Net Profit is $1,074 Million which is growth of -74.3% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.1% | 6.7% | 6,067.6 | 5,439.5 | 6,004.8 | 5,382.4 | 5,232.5 | 4,386.3 | 4,348 | 3,722.8 | 3,435.3 | 2,963.7 | 2,493.7 | |||
Cost Of Rev. Ann. | 7.3% | 4.3% | 1,443.2 | 1,334.2 | 1,117.5 | 1,379.8 | 1,080.4 | 1,248.9 | 1,080.6 | 1,114.4 | 939.4 | 875.3 | 797.4 | 617.2 | |
Gross Profit Ann. | 3.2% | 7.4% | 5,069.1 | 4,733.4 | 4,322 | 4,625 | 4,302 | 3,983.6 | 3,305.7 | 3,233.6 | 2,783.4 | 2,560 | 2,166.3 | 1,876.5 | |
Operating Exp. Ann. | 7.2% | 9.3% | 3,239.5 | 3,097.2 | 2,841.9 | 2,896.4 | 2,512.8 | 2,396.8 | 1,989.1 | 1,994.9 | 1,710.7 | 1,537.3 | 1,382.5 | 1,233.8 | |
Operating Profit Ann. | -2.9% | 4.4% | 1,829.6 | 1,636.2 | 1,480.1 | 1,728.6 | 1,789.2 | 1,586.8 | 1,316.6 | 1,238.7 | 1,072.7 | 1,022.7 | 783.8 | 642.7 | |
108.8% | 81.2% | 138 | 148.4 | 100.5 | 49.6 | 16.3 | -1 | 7.6 | 11.5 | 2.1 | -2.9 | -8.4 | -9.3 | ||
Other Exp. Ann. | - | - | -511.7 | -32.5 | -180.1 | -38.1 | 116.2 | -407.5 | -83.7 | -313.4 | 15.1 | -37.5 | -11 | ||
PBT Ann. | -10.4% | 6.8% | 1,417.6 | 1,272.9 | 1,548.1 | 1,598.1 | 1,767.4 | 1,702 | 916.7 | 1,166.5 | 761.4 | 1,034.9 | 737.9 | 622.4 | |
Tax Ann. | -4% | 18.4% | 439 | 216.9 | 152.1 | 198.7 | 245.5 | 198.9 | 93.3 | 119.6 | 39.2 | 451.3 | 168.4 | 127.5 | |
-11% | 5.4% | 1,004.9 | 1,073.5 | 4,174.6 | 1,402.4 | 1,521.9 | 1,503.1 | 823.4 | 1,046.9 | 722.2 | 583.6 | 569.5 | 494.9 | ||
Diluted NI Avail to Com Stockholders Ann. | -11% | 5.4% | 1,004.9 | 1,073.5 | 4,174.6 | 1,402.4 | 1,521.9 | 1,503.1 | 823.4 | 1,046.9 | 722.2 | 583.6 | 569.5 | 494.9 | |
EPS Ann. | -10.4% | 6.7% | 1.8 | 7 | 2.3 | 2.5 | 2.4 | 1.3 | 1.7 | 1.2 | 0.9 | 0.9 | 0.8 | ||
Diluted EPS Ann. | -9.1% | 6.7% | 1.8 | 7 | 2.3 | 2.4 | 2.4 | 1.3 | 1.6 | 1.1 | 0.9 | 0.9 | 0.8 | ||
Number Of Shares End | -1.8% | -1.4% | 580.6 | 589.9 | 605.2 | 613 | 624.2 | 623.5 | 626.7 | 624.9 | 631.8 | 640.8 | 647.4 | ||
Total Exp. Ann. | 7.2% | 7.6% | 4,431.4 | 3,959.4 | 4,276.2 | 3,593.2 | 3,645.7 | 3,069.7 | 3,109.3 | 2,650.1 | 2,412.6 | 2,179.9 | 1,851 | ||
Net Income Continuing Discontinued Operations Ann. | -11% | 5.4% | 1,004.9 | 1,073.5 | 4,174.6 | 1,402.4 | 1,521.9 | 1,503.1 | 823.4 | 1,046.9 | 722.2 | 583.6 | 569.5 | 494.9 | |
Normalized Income Ann. | -1.5% | 4.6% | 1,463.7 | 1,487.3 | 1,436.9 | 1,564.2 | 1,555.7 | 1,402.2 | 1,188.1 | 1,123.6 | 1,018.5 | 574.5 | 598.8 | 504.2 | |
Interest Income Ann. | 68.2% | 48.5% | 168.8 | 120.3 | 67.2 | 35.5 | 17.4 | 23.4 | 32.2 | 32 | 20.3 | 10.8 | 7.9 | ||
Interest Ann. | 2% | 5.2% | 20.4 | 19.8 | 17.6 | 19.2 | 18.4 | 15.8 | 20.7 | 29.9 | 23.2 | 19.2 | 17.2 | ||
EBITDA Ann. | -9% | 6.9% | 1,652.2 | 1,449.9 | 1,723.1 | 1,760.6 | 1,926.2 | 1,855.2 | 1,039.7 | 1,276.5 | 868.7 | 1,140 | 828.3 | 705.4 | |
Reconciled Cost Of Rev. Ann. | 7.3% | 4.3% | 1,443.2 | 1,334.2 | 1,117.5 | 1,379.8 | 1,080.4 | 1,248.9 | 1,080.6 | 1,114.4 | 939.4 | 875.3 | 797.4 | 617.2 | |
Reconciled Depr. Ann. | 3.9% | 7.9% | 165.5 | 156.6 | 155.2 | 144.9 | 139.6 | 134.8 | 107.2 | 89.3 | 77.4 | 81.9 | 71.2 | 65.8 | |
Profit From Continuing Operations Ann. | -11.1% | 5.4% | 1,003.6 | 1,069.4 | 4,169.7 | 1,399.4 | 1,521.9 | 1,503.1 | 823.4 | 1,046.9 | 722.2 | 583.6 | 569.5 | 494.9 | |
Normalized EBITDA Ann. | 0% | 6.3% | 2,292.2 | 1,964.8 | 1,763 | 1,945.3 | 1,965.4 | 1,740.9 | 1,445.8 | 1,362 | 1,181.1 | 1,124.8 | 866.2 | 717.1 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
11.5%
2Y CAGR
0.5%
3Y CAGR
4.1%
5Y CAGR
6.7%
7Y CAGR
7.2%
10Y CAGR
9.3%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
-74.3%
2Y CAGR
-12.5%
3Y CAGR
-11%
5Y CAGR
5.4%
7Y CAGR
5.8%
10Y CAGR
8.1%
Net Profit Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
9%
2Y CAGR
3.4%
3Y CAGR
7.2%
5Y CAGR
9.3%
7Y CAGR
8.8%
10Y CAGR
9.6%
Operating Expenses Annual Cr growth is stable compared to historical averages.
Edwards Lifesciences balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund Edwards Lifesciences Dec-2025 Total Shareholders Fund is $10,338 Million which is growth of 3.4% YoY.
- POSITIVE
Total Assets Edwards Lifesciences Dec-2025 Total Assets is $13,697 Million which is growth of 4.9% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
18.2% | 13.6% | 13,697.2 | 13,055.3 | 9,363.2 | 8,292.5 | 8,502.6 | 7,237.1 | 6,488.1 | 5,323.7 | 5,695.8 | 4,510 | 4,059.3 | ||
10.6% | 4.8% | 3,359.6 | 2,992.4 | 2,643.8 | 2,485.8 | 2,666.7 | 2,662.8 | 2,339.8 | 2,183.3 | 2,739.6 | 1,891 | 1,556.2 | ||
21.2% | 17.7% | 10,337.6 | 9,998.4 | 6,650 | 5,806.7 | 5,835.9 | 4,574.3 | 4,148.3 | 3,140.4 | 2,956.2 | 2,619 | 2,503.1 | ||
Total Capitalization Ann. | 19.5% | 16.2% | 10,935.9 | 10,596.1 | 7,247 | 6,403 | 6,431.6 | 5,169.3 | 4,742.7 | 3,734.2 | 3,394.6 | 3,441.3 | 3,103 | |
Tangible Assets Ann. | 19.5% | 19.4% | 7,440.8 | 7,045.1 | 4,968.1 | 4,357.2 | 4,344.4 | 3,069.7 | 2,644.1 | 1,685 | 1,361.7 | 1,788.1 | 1,669.4 | |
Working Capital Ann. | 33.4% | 17.5% | 4,925.2 | 4,780.2 | 2,840.3 | 2,073.4 | 2,148.4 | 2,197.1 | 2,081.6 | 1,410.3 | 1,129.2 | 1,707.5 | 1,571.7 | |
Invested Capital Ann. | 19.5% | 16.2% | 10,935.9 | 10,596.1 | 7,247 | 6,403 | 6,431.6 | 5,169.3 | 4,742.7 | 3,734.2 | 3,992.6 | 3,441.3 | 3,103 | |
Tangible Book Value Ann. | 19.5% | 19.4% | 7,440.8 | 7,045.1 | 4,968.1 | 4,357.2 | 4,344.4 | 3,069.7 | 2,644.1 | 1,685 | 1,361.7 | 1,788.1 | 1,669.4 | |
Borrowings Ann. | 0.7% | 0.3% | 705.4 | 700 | 694.9 | 691.3 | 690.3 | 694.9 | 678.8 | 593.8 | 1,036.4 | 822.3 | 599.9 | |
Net Debt Ann. | - | - | - | - | - | - | - | - | - | - | 218.1 | - | - | |
Share Issued Ann. | 0.6% | 0.7% | 658.7 | 654.8 | 650.5 | 646.3 | 642 | 636.4 | 654.3 | 645.6 | 636 | 727.8 | 717.3 | |
Number Of Shares End | -1.8% | -1.4% | 580.6 | 589.9 | 605.2 | 613 | 624.2 | 623.5 | 626.7 | 624.9 | 631.8 | 640.8 | 647.4 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
4.9%
2Y CAGR
20.9%
3Y CAGR
18.2%
5Y CAGR
13.6%
7Y CAGR
14.5%
10Y CAGR
12.9%
Total Assets Annual growth is lower than historical averages.
Total Current Liabilities Ann.
1Y CHG
20.5%
2Y CAGR
23.2%
3Y CAGR
21.1%
5Y CAGR
15.2%
7Y CAGR
10.9%
10Y CAGR
14.3%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
3.4%
2Y CAGR
24.7%
3Y CAGR
21.2%
5Y CAGR
17.7%
7Y CAGR
18.6%
10Y CAGR
15.2%
Total ShareHolders Funds Annual growth is lower than historical averages.
Edwards Lifesciences ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Edwards Lifesciences Book Value Per Share is $18 which is growth of -0.9% YoY.
- NEUTRAL
ROE Edwards Lifesciences ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | 37.24% | 15.89% | 18.12% | 19.10% | 12.00% | 17.73% | 13.11% | 11.44% | 13.29% | 13.05% | |
ROE Ann. % | - | - | - | 50.15% | 22.52% | 26.14% | 28.88% | 18.88% | 28.73% | 23.69% | 20.94% | 22.24% | 21.08% | |
ROIC % | - | - | - | 3.1 | 5 | 6 | 5.3 | 5.8 | 6 | 0.2 | -0.1 | 4.7 | 4.6 | |
OPM Ann. % | -6.7% | -2.1% | 26.97% | 27.21% | 28.79% | 33.24% | 30.33% | 30.02% | 28.49% | 28.81% | 29.77% | 26.45% | 25.77% | |
Inventory Turnover Ratio Ann. | - | - | - | 1 | 1.4 | 1.4 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | |
Asset Turnover Ann. % | - | - | - | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
Working Capital Turnover Ann. | -22.7% | -9.7% | 1.2 | 1.1 | 2.1 | 2.6 | 2.4 | 2 | 2.1 | 2.6 | 3 | 1.7 | 1.6 | |
Quick Ratio Ann. | - | - | - | 3.1 | 2.1 | 1.9 | 2.1 | 2.2 | 2.3 | 1.7 | 1.3 | 3.2 | 3.3 | |
Current Ratio Ann. | - | - | - | 4.2 | 3.4 | 3 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | |
Interest Coverage Ratio Ann. | - | - | - | 79.2 | 91.8 | 93.1 | 93.5 | 59 | 57.4 | 26.5 | 45.6 | 39.4 | 37.2 | |
LT Debt To Equity Ann. | - | - | - | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Edwards Lifesciences cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Cash From Operating Activity Edwards Lifesciences Dec-2025 Cash From Operating Activity is $1,595 Million which is growth of 194.2% YoY.
- NEGATIVE
Net Cash Flow Edwards Lifesciences Dec-2025 Net Cash Flow is $-74 Million which is growth of -104.0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9.4% | 8.6% | 1,595.2 | 542.3 | 895.8 | 1,218.2 | 1,732.1 | 1,054.3 | 1,179.4 | 926.8 | 1,000.7 | 704.4 | 549.7 | ||
- | - | -712.9 | 2,312.9 | 173.8 | 252.3 | -1,722.5 | -531.1 | -595.8 | 76.7 | -647.2 | -211.7 | -316.1 | ||
- | - | -956.8 | -983 | -711 | -1,584.5 | -356.3 | -486.9 | -115.6 | -1,101.2 | -473.2 | -268.5 | -158.6 | ||
Cash Plus Cash Eqv. End Of Year Ann. | 56.1% | 19.6% | 2,939.5 | 3,058.8 | 1,148 | 772.6 | 867.4 | 1,200.2 | 1,179.1 | 714.1 | 818.3 | 930.1 | 718.4 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | - | -74.5 | 1,872.2 | 358.6 | -114 | -346.7 | 36.3 | 468 | -97.7 | -119.7 | 224.2 | 75 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | 52.2% | 20.9% | 3,058.8 | 1,148 | 772.6 | 867.4 | 1,200.2 | 1,184.4 | 714.1 | 818.3 | 930.1 | 718.4 | 653.8 | |
Income Tax Paid Supplemental Data Ann. | - | - | - | 1,196.1 | 470.1 | 504.1 | - | - | 61.5 | 223.7 | 143.7 | 99.9 | 86.9 | |
Interest Paid Supplemental Data Ann. | - | - | - | 19.6 | 19.9 | 19.3 | - | - | 19.9 | 30.1 | 19.9 | 16.1 | 17.2 | |
Capex Ann. | - | - | -260.2 | -282.4 | -266.3 | -264.8 | -329.8 | -407.3 | -278.4 | -241.7 | -175.5 | -217.4 | -106.5 | |
Issuance Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Issuance Of Debt Ann. | - | - | - | - | 5.2 | 16.2 | 18.9 | 688 | 994.7 | 253.5 | 31.4 | |||
Repayment Of Debt Ann. | - | - | - | - | -0.3 | -0.2 | -7 | -17 | -28.9 | -1,125.3 | -818.4 | -31.4 | -29.5 | |
Repurchase Of Capital Stock Ann. | - | - | -893.4 | -1,159.4 | -879.6 | -1,727.1 | -512.8 | -625.4 | -263.3 | -795.5 | -763.3 | -662.3 | -280.1 | |
Free Cash Flow Ann. | 11.9% | 15.6% | 1,335 | 259.9 | 629.5 | 953.4 | 1,402.3 | 647 | 901 | 685.1 | 825.2 | 487 | 443.2 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
194.2%
2Y CAGR
33.4%
3Y CAGR
9.4%
5Y CAGR
8.6%
7Y CAGR
8.1%
10Y CAGR
11.2%
Cash from Operating Activity Annual growth is higher than historical averages.